Sources & References
Sites consulted while researching, cross-auditing, and verifying the protocols in this guide.
Tier 1, community protocol DBs
- researchdosing.com
- peptidedosages.com
- thepeptidereport.com
- peptidedosingprotocols.com
- calcmypeptide.com
- seekpeptides.com
- peptides.id
Tier 2, pharmacy / clinic
- empowerpharmacy.com
- olympiapharmacy.com
- agelessrx.com
- fagronacademy.us
- defymedical.com
- walnutcreekaesthetics.com
- jinfiniti.com
- tailormadecompounding.com
Tier 3, FDA / clinical primary
- dailymed.nlm.nih.gov
- accessdata.fda.gov
- pubmed.ncbi.nlm.nih.gov
- pmc.ncbi.nlm.nih.gov
- clinicaltrials.gov
- ema.europa.eu
Tier 4, reference / encyclopedic
- en.wikipedia.org
- drugs.com
- rxlist.com
Tier 6, protocol-adjacent
- peptidedeck.com
- seekpeptides.com
- perfectb.com
- glp3planner.com
- peptide-db.com
- highpeptides.com
- peptidewiki.co
Gov / edu technique
- cdc.gov (SubQ technique, Pink Book Ch 6)
- ncbi.nlm.nih.gov/books (injection best practices, NBK138495)
Aesthetic / clinic / consumer
- my.clevelandclinic.org
- emedicine.medscape.com
- go.drugbank.com
- aboutnad.com
- peachiv.com
- thinworks.com
- innerbody.com
- peptides.org
- usada.org
- realpeptides.co
- medsbase.com
- stealthbt.com
- curefa.org
- peptideinitiative.com
- cellgenic.com
2026-06 catalog expansion (42 compounds)
Dosing/recon first built from the community DBs (Tier 1), then a primary-source verification pass (Jul 2026) checked the higher-risk compounds (in-trials incretins, GH secretagogues, experimental-safety claims) against ClinicalTrials.gov, PubMed, Consensus, and FDA labels; the Survodutide ceiling was corrected to the trial dose. Steroids use standard TRT/cycle refs; cosmetics standard topical %; remaining bioregulators/experimental peptides stay community-sourced, flagged where no validated human dose exists.
June 2026 update sources
Lilly & Novo Nordisk press releases (TRIUMPH-1/TRIUMPH-4, SURMOUNT-5, Zepbound OSA, Ozempic CKD/FLOW, Wegovy MASH); The Lancet (TRANSCEND-T2D-1, Jun 2026); FDA approvals (Forzinity, Egrifta WR, Skytrofa adult GHD); EMA/WHO NAION advisory.
July 2026 update
Folded the men-vs-women guide into the doc: a Men/Women dose note on every peptide page (steroids carry explicit virilization warnings), plus new Understanding Your Bloodwork and Peptides by Sex & Life Stage reference pages. Per-peptide sex-difference sources added as clickable PubMed links; every reference link re-checked for dead URLs. References moved to the bottom of each page. Doc renamed Peptide Protocol Reference → The Complete Peptide Guide. Added a “Combining Peptides in One Syringe” reference section (pages 8–10): the co-mixing science, mix / care / never tables, an all-91 group verdict table, and drawing technique.
August 2026 update
FDA PCAC outcome (Jul 23–24, 2026): the advisory panel recommended six of seven peptides for the 503A compounding bulks list; BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax; and rejected DSIP (emideltide); per-peptide warnings updated with the vote tallies. Advisory only, not binding; FDA rulemaking is pending (likely 2027). NSAID interaction corrected: BPC-157 heals independently of the prostaglandin/COX pathway, so NSAIDs don’t “blunt” it; the real reason to skip NSAIDs during a healing cycle is that NSAIDs slow tissue healing on their own (use acetaminophen for pain).
Sex-based dosing (men vs women)
Cited on each peptide page as clickable PubMed searches.
- GH / IGF-1 & estrogen route: Span 2000, Weissberger 1991
- GLP-1 & testosterone: Jensterle 2020
- HCG / male fertility: Coviello 2005
- Kisspeptin (both sexes): Abbara / Dhillo 2015
- Bremelanotide / PT-141: Kingsberg 2019 (women), Wessells 2000 (men)
- Melanocortins: Dorr 1996
Community discussion (not used for verification)
- reddit.com/r/Peptides, anecdotal; intentionally not retrieved for primary protocol verification.
Disclaimer
Informational only. Not medical advice. Consult a qualified clinician before beginning any protocol. Compounded / research peptides are not equivalent to FDA-approved clinical-trial product.